Cognitive Stimulation Therapy (CST) enhances the effects of Alzheimer’s disease medicine
Copenhagen, Denmark, March 24, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · CST in combination with cholinesterase inhibitors shows to be more effective against dementia in Alzheimer’s disease (AD) than medicine alone · This is promising for combining Brain+ CST products with AD medicine in multi-modal treatment plans to improve health outcomes for patients · Combination treatments could enhance the value of product portfolios for pharmaceutical companies and could thus lead to strategic partnerships for Brain+A key finding from the recently released 2[nd] systematic Cochrane